Setting

Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity

Published: 30 Nov 2021 | Report Code: 10248260 | Pages: 121

Europe biosimilars market was valued at $5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions. Highlighted with 37 tables and 57 figures, this 121-page report “Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country. Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Recombinant Non-glycosylated Biosimilars o Insulin o Recombinant Human Growth Hormone (rHGH) o Granulocyte Colony Stimulating Factor o Interferon • Recombinant Glycosylated Biosimilars o Monoclonal Antibodies (mAb) o Erythropoietin (EPO) o Follicle Stimulating Hormone • Recombinant Peptides and Others o Tumor Necrosis Factor (TNF)-Inhibitor o Parathyroid Hormone o Enzymes, Immunomodulators, GnRH Analogs and Others Based on Indication, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Cancer • Autoimmune Disease • Blood Disorder • Diabetes • Growth Hormone Deficiency • Infectious Diseases • Other Indications Based on Manufacturing, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Contract Manufacturing • Inhouse Manufacturing Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Hospitals and Clinics • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AMEGA Biotech S.A. Apotex Inc. Biocon Ltd Biogen Inc. Boehringer Ingelheim Celltrion, Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company Intas Pharmaceuticals Ltd. LG Chem, Ltd. Merck and Co. Inc. Mylan N.V. Pfizer Inc. Samsung Biologics Co., Ltd. Sandoz International GmbH STADA Arzneimittel AG Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	22
2.1.2 Impact of COVID-19 on the Market	25
2.2 Major Growth Drivers	27
2.3 Market Restraints and Challenges	32
2.4 Emerging Opportunities and Market Trends	35
2.5 Porter’s Fiver Forces Analysis	39
3 Segmentation of Europe Market by Product Type	43
3.1 Market Overview by Product Type	43
3.2 Recombinant Non-glycosylated Biosimilars	45
3.2.1 Insulin	47
3.2.2 Recombinant Human Growth Hormone (rHGH)	48
3.2.3 Granulocyte Colony Stimulating Factor	49
3.2.4 Interferon	50
3.3 Recombinant Glycosylated Biosimilars	51
3.3.1 Monoclonal Antibodies (mAb)	52
3.3.2 Erythropoietin (EPO)	53
3.3.3 Follicle Stimulating Hormone	54
3.4 Recombinant Peptides and Others	55
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor	56
3.4.2 Parathyroid Hormone	57
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others	58
4 Segmentation of Europe Market by Indication	59
4.1 Market Overview by Indication	59
4.2 Cancer	61
4.3 Autoimmune Disease	62
4.4 Blood Disorder	63
4.5 Diabetes	64
4.6 Growth Hormone Deficiency	65
4.7 Infectious Diseases	66
4.8 Other Indications	67
5 Segmentation of Europe Market by Manufacturing	68
5.1 Market Overview by Manufacturing	68
5.2 Contract Manufacturing	70
5.3 Inhouse Manufacturing	71
6 Segmentation of Europe Market by End User	72
6.1 Market Overview by End User	72
6.2 Hospitals and Clinics	74
6.3 Research Institutes	75
6.4 Other End Users	76
7 European Market 2019-2030 by Country	77
7.1 Overview of European Market	77
7.2 Germany	82
7.3 U.K.	85
7.4 France	88
7.5 Spain	90
7.6 Italy	92
7.7 Russia	94
7.8 Rest of European Market	96
8 Competitive Landscape	98
8.1 Overview of Key Vendors	98
8.2 New Product Launch, Partnership, Investment, and M&A	102
8.3 Company Profiles	103
AMEGA Biotech S.A.	103
Apotex Inc.	105
Biocon Ltd	106
Biogen Inc.	107
Boehringer Ingelheim	108
Celltrion, Inc.	109
Dr. Reddy’s Laboratories Ltd.	110
Eli Lilly and Company	111
Intas Pharmaceuticals Ltd.	112
LG Chem, Ltd.	113
Merck and Co. Inc.	114
Mylan N.V.	115
Pfizer Inc.	116
Samsung Biologics Co., Ltd.	117
Sandoz International GmbH	118
STADA Arzneimittel AG	119
Teva Pharmaceutical Industries Ltd.	120
RELATED REPORTS	121
List Of Tables:

Table 1.  Snapshot of Europe Biosimilars Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	23
Table 3. World Health Spending by Region, $ bn, 2013-2020	31
Table 4.  Main Product Trends and Market Opportunities in Europe Biosimilars Market	35
Table 5. Europe Biosimilars Market by Product Type, 2019-2030, $ mn	43
Table 6. Europe Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn	46
Table 7. Europe Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn	51
Table 8. Europe Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn	55
Table 9. Europe Biosimilars Market by Indication, 2019-2030, $ mn	59
Table 10. Europe Biosimilars Market by Manufacturing, 2019-2030, $ mn	68
Table 11. Europe Biosimilars Market by End User, 2019-2030, $ mn	72
Table 12. Europe Biosimilars Market by Country, 2019-2030, $ mn	79
Table 13. Approved Biosimilars in Europe	80
Table 14. Germany Biosimilars Market by Product Type, 2019-2030, $ mn	83
Table 15. Germany Biosimilars Market by Indication, 2019-2030, $ mn	83
Table 16. Germany Biosimilars Market by End User, 2019-2030, $ mn	83
Table 17. U.K. Biosimilars Market by Product Type, 2019-2030, $ mn	87
Table 18. U.K. Biosimilars Market by Indication, 2019-2030, $ mn	87
Table 19. U.K. Biosimilars Market by End User, 2019-2030, $ mn	87
Table 20. France Biosimilars Market by Product Type, 2019-2030, $ mn	89
Table 21. France Biosimilars Market by Indication, 2019-2030, $ mn	89
Table 22. France Biosimilars Market by End User, 2019-2030, $ mn	89
Table 23. Spain Biosimilars Market by Product Type, 2019-2030, $ mn	91
Table 24. Spain Biosimilars Market by Indication, 2019-2030, $ mn	91
Table 25. Spain Biosimilars Market by End User, 2019-2030, $ mn	91
Table 26. Italy Biosimilars Market by Product Type, 2019-2030, $ mn	93
Table 27. Italy Biosimilars Market by Indication, 2019-2030, $ mn	93
Table 28. Italy Biosimilars Market by End User, 2019-2030, $ mn	93
Table 29. Russia Biosimilars Market by Product Type, 2019-2030, $ mn	95
Table 30. Russia Biosimilars Market by Indication, 2019-2030, $ mn	95
Table 31. Russia Biosimilars Market by End User, 2019-2030, $ mn	95
Table 32. Biosimilars Market in Rest of Europe by Country, 2019-2030, $ mn	97
Table 33. Breakdown of World Market by Key Vendor, 2020, %	100
Table 34. AMEGA Biotech S.A.: Company Snapshot	103
Table 35. AMEGA Biotech S.A.: Business Segmentation	103
Table 36. AMEGA Biotech S.A.: Product Portfolio	104
Table 37. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn	104
List Of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. Europe Biosimilars Market, 2019-2030, $ mn	19
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019	20
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area	20
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area	21
Figure 8. Impact of COVID-19 on Business	25
Figure 9. Primary Drivers and Impact Factors of Europe Biosimilars Market	27
Figure 10.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	30
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060	30
Figure 12. Primary Restraints and Impact Factors of Europe Biosimilars Market	32
Figure 13. Investment Opportunity Analysis	36
Figure 14. Porter’s Fiver Forces Analysis of Europe Biosimilars Market	39
Figure 15. Breakdown of Europe Biosimilars Market by Product Type, 2019-2030, % of Revenue	44
Figure 16. Europe Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%)	44
Figure 17. Europe Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn	45
Figure 18. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn	47
Figure 19. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn	48
Figure 20. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn	49
Figure 21. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn	50
Figure 22. Europe Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn	51
Figure 23. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn	52
Figure 24. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn	53
Figure 25. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn	54
Figure 26. Europe Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn	55
Figure 27. Europe Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn	56
Figure 28. Europe Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn	57
Figure 29. Europe Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn	58
Figure 30. Breakdown of Europe Biosimilars Market by Indication, 2019-2030, % of Sales Revenue	60
Figure 31. Europe Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%)	60
Figure 32. Europe Biosimilars Market by Indication: Cancer, 2019-2030, $ mn	61
Figure 33. Europe Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn	62
Figure 34. Europe Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn	63
Figure 35. Europe Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn	64
Figure 36. Europe Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn	65
Figure 37. Europe Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn	66
Figure 38. Europe Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn	67
Figure 39. Breakdown of Europe Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue	69
Figure 40. Europe Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%)	69
Figure 41. Europe Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn	70
Figure 42. Europe Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn	71
Figure 43. Breakdown of Europe Biosimilars Market by End User, 2019-2030, % of Revenue	73
Figure 44. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%)	73
Figure 45. Europe Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn	74
Figure 46. Europe Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn	75
Figure 47. Europe Biosimilars Market by End User: Other End Users, 2019-2030, $ mn	76
Figure 48. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue	78
Figure 49. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)	79
Figure 50.  Biosimilars Market in Germany, 2019-2030, $ mn	82
Figure 51.  Biosimilars Market in U.K., 2019-2030, $ mn	85
Figure 52.  Biosimilars Market in France, 2019-2030, $ mn	88
Figure 53.  Biosimilars Market in Spain, 2019-2030, $ mn	90
Figure 54.  Biosimilars Market in Italy, 2019-2030, $ mn	92
Figure 55.  Biosimilars Market in Russia, 2019-2030, $ mn	94
Figure 56.  Biosimilars Market in Rest of Europe, 2019-2030, $ mn	96
Figure 57. Growth Stage of Europe Biosimilars Industry over the Forecast Period	98
Key Players (this may not be a complete list and extra companies can be added upon request): 
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd. 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)